Surgery & Radiation: New Options, New Questions

New options for surgery and radiation cause debate in early-stage breast cancer.

Talk about this article with other patients, caregivers, and advocates in the Breast Cancer CURE discussion group.
There was something in her sentinel lymph node, doctors told Sandra Fish a few days after her lumpectomy in December 2003. The node looked clear during surgery, she says, but further testing found a shadow of cancer.

“They called it a trace, a microscopic trace,” says Fish. Did that mean a greater risk of her cancer spreading? Did it suggest more aggressive treatment, or further surgical exploration of lymph nodes, which might create uncomfortable side effects?

For early-stage breast cancer, it’s not just chemotherapy treatments that are the subject of debate. Researchers are also struggling to decipher the cryptic information stored in sentinel lymph nodes, how to advise patients on surgical options, and the best techniques for delivering radiation therapy.

“We have significantly more data to sift through to try to give our patients the best advice,” says Patrick Moran, MD, an oncologist with the Rocky Mountain Cancer Center and one of Fish’s doctors.

Today, many clinicians rely on information from one or two sentinel lymph nodes—the ones most intimately connected with the breast— identified and removed during surgery and dissected for evidence that cancerous cells have moved beyond the breast. Increasingly sophisticated laboratory tests can find faint evidence of cancer that might not have been caught a decade ago—a fact that has put clinicians in a quandary since prospective trials have yet to show if those cells, termed “micrometastases,” pose any risk.

Certain tests to more easily detect only a few cancer cells in sentinel lymph node biopsy specimens are not yet used for that very reason, says Anthony Elias, MD, an oncology researcher at the University of Colorado. “It’s really uncertain that it shows anything clinically relevant, yet it may push treatment, push more chemotherapy than is necessarily warranted.”

Fish decided against additional therapy. One oncologist said “it would be overkill” to add more chemotherapy because of a microscopic trace, says Fish, who is cancer-free today.

Last year, University of Minnesota researchers reported that many more patients with unilateral breast cancer were seeking double mastectomies despite no clinical evidence that the preventive approach of removing the unaffected breast increases survival, given the existing breast cancer diagnosis and overall low risk of death due to second primary tumors. The rate of contralateral surgery for unilateral cancer increased from 4.2 percent in 1998 to 11 percent in 2003.

The study generated a flurry of debate. In a letter published this year in the Journal of Clinical Oncology, one Greek team called for oncologists to rethink the practice of “radical surgery,” especially before offering genetic testing and counseling. In his practice, Moran says, most of the patients opting for double mastectomies carry the BRCA1 or 2 gene, which both carry an increased susceptibility for breast and ovarian cancers.

Bilateral mastectomy does, however, reduce a woman’s chances of recurrence, and the Minnesota authors countered that there are many circumstances in which contralateral surgery is, in fact, a rational choice.

Talk about this article with other patients, caregivers, and advocates in the Breast Cancer CURE discussion group.
CURE wants to hear from you! We are inviting you to Share Your Story with the readers of CURE. Submit your personal experience with cancer by visiting Share Your Story
Not yet receiving CURE in your mailbox? Sign up to receive CURE Magazine by visiting